CV Sciences, Inc. Comments on Latest Research Citing Cannabidiol in Reducing the Risk of Post-Traumatic Stress Disorder

San Diego, California, UNITED STATES

LAS VEGAS, Sept. 26, 2017 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we") is pleased to highlight yet another study identifying additional therapeutic opportunities of cannabidiol (CBD), which include the potential to prevent post-traumatic stress disorder (PTSD).

Researchers at the Federal University of Parana, Santa Catarina, and the University of Sao Paulo, have preclinical evidence that when given immediately after a fearful event, CBD can significantly reduce the conditioned fear expression and fear generalization and the relative resistance to extinction of the fear memory. These findings have important implications for the possible role of CBD in reducing PTSD. Their research suggests the mechanism of action is through CBD’s known effects on increasing the endocannabinoid, anandamide, which activates CB1 and CB2 receptors to disrupt the consolidation of different fear memories. Importantly, the CBD had to be administered immediately after the fearful event to be effective.

PTSD is a severe anxiety disorder, which can lead to impairment in daily functioning and suicidal behavior. In PTSD, fear repeatedly returns and may be recalled vividly in the form of flashbacks, even in the absence of stimuli. Other symptoms include difficulty sleeping and feelings of detachment. PTSD can be either acute, lasting one month to three months, or chronic, lasting for more than three months after the traumatic incident. The only FDA-approved drugs for the treatment of PTSD are the selective serotonin reuptake inhibitors (SSRIs), sertraline (Zoloft, Pfizer), and paroxetine HCl (Paxil, GlaxoSmithKline), which show variable levels of efficacy, but there is no approved drug for prevention of PTSD after a traumatic event. According to the National Center for PTSD, 7 or 8 out of every 100 people will experience PTSD at some point in their lives.

Amy McCord, Director of Drug Development at CV Sciences commented, “These recent findings are consistent with other research identifying that people suffering from PTSD have lower levels of anandamide and indicate that restoring the CB1 signaling could provide a potential role for CBD in PTSD prevention. Research into CBD and its effects on various disease states is mounting, and studies like these support new potential development opportunities for CBD as a pharmaceutical modality.”

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI), operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc., has primary offices and facilities in San Diego, California, and Las Vegas, Nevada. Additional information is available from or by visiting


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks, uncertainties. 


Robert Haag
Managing Director
IRTH Communications